AU6813694A - Use of green porphyrins in ocular diagnosis and therapy - Google Patents

Use of green porphyrins in ocular diagnosis and therapy

Info

Publication number
AU6813694A
AU6813694A AU68136/94A AU6813694A AU6813694A AU 6813694 A AU6813694 A AU 6813694A AU 68136/94 A AU68136/94 A AU 68136/94A AU 6813694 A AU6813694 A AU 6813694A AU 6813694 A AU6813694 A AU 6813694A
Authority
AU
Australia
Prior art keywords
therapy
green porphyrins
ocular diagnosis
ocular
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68136/94A
Inventor
Evangelos S Gragoudas
Joan W Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Eye and Ear
Original Assignee
Massachusetts Eye and Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye and Ear Infirmary filed Critical Massachusetts Eye and Ear Infirmary
Publication of AU6813694A publication Critical patent/AU6813694A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU68136/94A 1994-03-14 1994-03-14 Use of green porphyrins in ocular diagnosis and therapy Abandoned AU6813694A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/002639 WO1995024930A1 (en) 1994-03-14 1994-03-14 Use of green porphyrins in ocular diagnosis and therapy

Publications (1)

Publication Number Publication Date
AU6813694A true AU6813694A (en) 1995-10-03

Family

ID=22242340

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68136/94A Abandoned AU6813694A (en) 1994-03-14 1994-03-14 Use of green porphyrins in ocular diagnosis and therapy

Country Status (3)

Country Link
AU (1) AU6813694A (en)
CA (2) CA2185644C (en)
WO (1) WO1995024930A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
JP3845469B2 (en) 1996-02-21 2006-11-15 明治製菓株式会社 Administration agent for occlusion of neovascularization of the fundus
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
WO1997035617A1 (en) * 1996-03-26 1997-10-02 Pharmacyclics, Inc. Use of a texaphyrin in photodynamic therapy of pigment-related lesions
US6043237A (en) * 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
EP1005369B1 (en) * 1996-12-11 2003-05-21 Pharmacyclics, Inc. Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
US6351663B1 (en) 1999-09-10 2002-02-26 Akorn, Inc. Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation
US6944493B2 (en) 1999-09-10 2005-09-13 Akora, Inc. Indocyanine green (ICG) compositions and related methods of use
WO2001017561A1 (en) * 1999-09-10 2001-03-15 Akorn, Inc. Fluorescent dye angiography and dye-enhanced photocoagulation
US6443976B1 (en) * 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
EP1267935A2 (en) * 2000-01-12 2003-01-02 Light Sciences Corporation Novel treatment for eye disease
ES2311507T3 (en) 2000-02-10 2009-02-16 MASSACHUSETTS EYE & EAR INFIRMARY PHOTODYNAMIC THERAPY FOR TREATMENT OF OPHTHALMIC AFFECTIONS.
AU2006203034B2 (en) * 2000-02-10 2006-09-07 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
PT1357946E (en) 2001-02-06 2008-06-27 Quadra Logic Tech Inc Photodynamic therapy with reduced fluence rate
US7753943B2 (en) 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
OA12720A (en) * 2001-11-09 2006-06-27 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases.
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
CN1708266A (en) 2002-10-03 2005-12-14 光科学公司 System and method for excitation of photoreactive compounds in eye tissue

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy

Also Published As

Publication number Publication date
CA2536069A1 (en) 1995-09-21
CA2536069C (en) 2008-06-03
CA2185644C (en) 2011-04-12
CA2185644A1 (en) 1995-09-21
WO1995024930A1 (en) 1995-09-21

Similar Documents

Publication Publication Date Title
AU6813694A (en) Use of green porphyrins in ocular diagnosis and therapy
AU7605396A (en) Cannula with associated filter and methods of use during cardiac surgery
AU3391395A (en) Morpholine derivatives and their use as therapeutic agents
IL113844A (en) N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS
AU4054297A (en) Manipulations of nitrosative and oxidatives stress in the treatment of disease
AU3784193A (en) Reduction of swelling in hemorrhoidal tissues
AU3102097A (en) Spiro-piperidine derivatives and their use as therapeutic agents
GB9518115D0 (en) Triazole derivatives and their use as therapeutic agents
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU6566094A (en) Heterocyclic derivatives in the treatment of ischaemia and related diseases
IL123600A0 (en) 2(1H)-Quinolone derivatives their preparation and their use in therapy
AU4611199A (en) Porphyrin derivatives and their use in photodynamic therapy and mri diagnosis
EP0691112A3 (en) Ophthalmic treatment apparatus and its use
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU4713497A (en) Use of hollow microcapsules in diagnosis and therapy
AU1945395A (en) Use of xylanase in baking
AU4410296A (en) Diagnosis of and therapy for hereditary haemorrhagic telangiectasia
AU3268197A (en) Spiro-piperidine derivatives and their use as therapeutic agents
IL128902A0 (en) N-(2-benzothiazolyl)-1-piperidineethanamine derivatives their preparation and their use in therapy
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
AU1413997A (en) Use of rc-9 in diagnosis and treatment of proliferative arterial disease
AU3628697A (en) Lipid-binding proteins and their therapeutic and diagnostic use
AU2992295A (en) Therapeutic method and compounds of use therein
AU3361595A (en) Formulation and use of carotenoids in treatment of cancer
AU641157B2 (en) 2-imino-thiadiazoline-5-sulphonamides and their use in the treatment of glaucoma